Brand profile · Biotechnology Research

MINIMUM bio

MINIMUM bio runs a Biotechnology Research operation from Sydney, NSW. Ownership is privately held; it publishes at minimumbio.com. It holds one address on record, all in Australia. The record counts 5 people. Tagged phage display, drug discovery and taget identification. One Australian registration (ABN) is a candidate match. The record links nine similar brands, most of them in Biotechnology Research.

Profile live Privately Held Founded 2022 1 registry match ABN 1 office country
Registry match · ABR

Key facts

Counted staff
5
self-reported 2–10 band
Founded
2022
4 years
Registry matches
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Privately Held
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 possible registrationThese are name matches on ABR. 1 registration share this brand's name; which one you contract with is a question for the register.
  • MINIMUM BIO PTY LTD

    ABN58658984555

    NSWMedium confidenceMatched on exact nameABR

Legal entities

MINIMUM bio: 1 registry entityMINIMUM bio is linked to 1 registry entity: MINIMUM BIO PTY LTD (ABN 58658984555, candidate).MINIMUM bioMINIMUM BIO PTY LTDABN 58658984555Candidate · Medium confidence
Show as table · MINIMUM bio: 1 registry entity
MINIMUM bio: 1 registry entity
MINIMUM BIO PTY LTDABN 58658984555
Confirmed matches0 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

MINIMUM bio is a biotech company that aims to revolutionize drug discovery by accelerating early phase R&D in the pharmaceutical sector, saving years and hundreds of millions of dollars in drug development costs.

MINIMUM bio has developed a versatile, high throughput discovery technology with broad applications in the development of new therapeutic products and the repositioning of existing drugs. The Company’s expertise and know-how is based on our phage display technology platform that permits us to rapidly identify proteins that bind to bioactive molecules of interest. The Company has repurposed antibody phage display for drug target discovery and believes that this platform is a powerful method that can also be used to identify protein targets of small molecules, biologics and other bioactive compounds, and has significant advantages over conventional and mass spectrometry-based approaches. Advantages include: increased speed, less background and less bias toward common, high-abundance, but low affinity targets. Over the past 15 years we have been improving and refining the Phage Display technique (‘Mercurious®’) to the point where we can now rapidly isolate the protein binding partner(s) for any small molecule, biologic or natural product.

Our flagship Mercurious platform is designed to create a new model for early-stage drug discovery. The platform harnesses an antibody drug discovery platform and repurposes it for drug target discovery, combining advances in molecular biology, next generation sequencing and machine learning into a single integrated architecture for rapid and agnostic drug target discovery with the goal of accelerating the rate of drug development.

The Mercurious platform builds on our core target identification technology and presents a seamless pipeline that will address target identification challenges for the global pharmaceutical industry in a customizable, scalable, and cost-competitive manner.

Specialties

All 8 specialties
  • phage display
  • drug discovery
  • taget identification
  • chemical genetics
  • chemical proteomics
  • target science
  • discovery biology
  • Accelerating Target Discovery

Locations

Country footprint

Offices in 1 countryCountry footprint: 1 country, primary AU. Codes: AU.1 countryprimary AUAU
Show as table · Offices in 1 country
Offices in 1 country
Countries1
Primary countryAU

All codes: AU

Addresses

  • AUSchool of Biotechnology and Biomolecular Sciences (BABS); Biological Sciences South Building (E26); Sydney, NSW 2052Primary

Grid intelligence Members

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss

People & contacts

2 employee profiles on record · names withheld.

Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.

Counts only. No names are stored here, and none are served.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under MINIMUM bio?

One New South Wales entity on the ABR. MINIMUM BIO PTY LTD (ABN 58 658 984 555), medium confidence.

How many people work at MINIMUM bio?

The record holds 5 counted staff profiles at January 2026, inside the self-reported 2–10 band.

Where does MINIMUM bio have offices?

One address on record, Australia only. Primary: School of Biotechnology and Biomolecular Sciences (BABS), Biological Sciences South Building (E26), Sydney, NSW 2052.

Has MINIMUM bio raised funding?

None linked to this brand.

What does MINIMUM bio list as its specialties?

Eight tags on the brand's own list, among them phage display, drug discovery and taget identification.

Which companies are listed alongside MINIMUM bio?

6 profiles list MINIMUM bio as a peer — 68th percentile in Biotechnology Research. It lists ten peers of its own. Skin2Neuron and PolySpine list it back.

What is MINIMUM bio's website?